Anti-CGRP therapies, erenumab, fremanezumab and galcanezumab, are being approved for use in a growing number of countries worldwide with varying arrangements for reimbursement. Eptinezumab and the gepants, ubrogepant, atogepant and rimegepant, are being assessed by regulatory agencies or are in clinical development.
|